BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed IDYA catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:a72f5ac84c185761d32d@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:IDYA P2/P3 readout (est.): IDE196 (Darovasertib) in Combination Wit
 h Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
DESCRIPTION:IDE196 (Darovasertib) in Combination With Crizotinib as First-l
 ine Therapy in Metastatic Uveal Melanoma\nNCT05987332 | PHASE2/PHASE3 | AC
 TIVE_NOT_RECRUITING | sponsor: IDEAYA Biosciences\nPrimary completion date
  (ESTIMATED)\; top-line results usually follow later.\nTicker IDYA (confid
 ence 0.9)\nSource: https://clinicaltrials.gov/study/NCT05987332\nSchedulin
 g/reference data from public records\; dates can move. Not investment\, le
 gal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05987332
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fbeab5597db0279540de@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:IDYA P1/P2 readout (est.): Study of IDE196 in Patients With Solid T
 umors Harboring GNAQ/11 Mutations or PRKC Fusions
DESCRIPTION:Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11
  Mutations or PRKC Fusions\nNCT03947385 | PHASE1/PHASE2 | RECRUITING | spo
 nsor: IDEAYA Biosciences\nPrimary completion date (ESTIMATED)\; top-line r
 esults usually follow later.\nTicker IDYA (confidence 0.9)\nSource: https:
 //clinicaltrials.gov/study/NCT03947385\nScheduling/reference data from pub
 lic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03947385
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
